Xtant Medical Holdings, Inc. (XTNT): auditor change — Xtant Medical dismisses Plante & Moran, appoints Grant Thornton as auditor

Xtant Medical Holdings, Inc.

Audit committee appointed Grant Thornton LLP as independent auditor on August 15, 2023, replacing Plante & Moran.
Plante & Moran notified the audit committee it is evaluating whether to continue its SEC audit practice in the company's industry.
No disagreements or reportable events occurred during the two most recent fiscal years or the interim period preceding dismissal.
Audit reports for 2022 and 2021 were unqualified with no adverse opinions or modifications.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Xtant Medical Holdings, Inc. engaged Grant Thornton LLP as its auditor.

Action: engagement
Auditor: Grant Thornton LLP

Exact text from the filing

On August 15, 2023, the Audit Committee of the Board of Directors of Xtant Medical Holdings, Inc. (the “Company”) appointed Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Xtant Medical Holdings, Inc. dismissed Plante & Moran, PLLC as its auditor.

Action: dismissal
Auditor: Plante & Moran, PLLC
Successor: Grant Thornton LLP

Exact text from the filing

dismissed Plante & Moran, PLLC (“Plante Moran”), as the Company’s independent registered public accounting firm, subject to Grant Thornton LLP’s standard client acceptance procedures, which were completed on August 18, 2023.

View on SEC.gov

Browse all auditor changes →

Xtant Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-029442

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.